denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: AbbVie Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Sanofi
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Antibody Therapy, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diversity, Equity, and Inclusion (DEI), Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Adverse Events
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Antibody Therapy, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diversity, Equity, and Inclusion (DEI), Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Adverse Events
Friday, December 6, 2024: 7:00 AM-10:00 AM
Room 6B
(San Diego Convention Center)
Chair:
Caitlin Costello, MD, University of California, San Diego
Disclosures:
Costello: BMS, Janssen, Karyopharm, Kite, Genentech, Pfizer: Honoraria; BMS; Harpoon; Janssen; Pfizer; Poseida; and Takeda: Research Funding; BMS; Genentech; Janssen; Karyopharm; Kite; and Pfizer: Consultancy.
Speaker:
Rahul Banerjee, MD, FACP, ARRAY(0xeed32cc)
Disclosures:
Banerjee: Abbvie; JNJ; Novartis; Pack Health; Prothena; Sanofi: Research Funding; Adaptive; BMS; Caribou Biosciences; Genentech; GSK; JNJ / Janssen; Karyopharm; Legend Biotech; Pfizer; Sanofi; SparkCures: Consultancy.
Keeping up with the vast emerging clinical data on myeloma is a big challenge; figuring out how to translate this data into practice is an even bigger one. If this is relatable, you won't want to miss this session! During this 60-minute event, two myeloma experts will provide you with practical, hands-on "how-to" strategies that you can implement with patients in your community practice as soon you get home from San Diego. Our expert faculty will provide their perspectives on a variety of nuanced treatment decisions: best use of anti-CD38 antibodies in newly diagnosed disease; sequencing considerations in subsequent lines of therapy; and understanding when/why/how to use the latest novel therapies—CAR T-cell therapies, bispecific antibodies, and XPO1 inhibitors. Faculty will also discuss disparities in myeloma care that may lead to suboptimal treatment outcomes in some underserved populations (according to their race, ethnicity, and socioeconomic status), and present some strategies to move the needle to reduce these disparities.
Bring your questions—the myeloma experts will do their best to address them, giving you more tools to improve your myeloma practice, and your patients' lives.
See more of: Friday Satellite Symposia